Viking Therapeutics: M&A Speculation Heats Up in Weight-Loss Drug Race
Published on 01/19/2026 at 11:53 | Redaktion boerse-global.de
Shares of Viking Therapeutics have posted significant gains, fueled by renewed takeover speculation within the obesity drug sector. This sentiment received a substantial boost from clear signals issued by industry giant Novo Nordisk. Concurrently, concrete clinical progress ensures the investment thesis is grounded in more than just rumor.
The global market for obesity therapies is expanding at a rapid pace. Analyst projections suggest it could surpass an annual value of $150 billion by the end of the decade. Consequently, major pharmaceutical firms are willing to commit substantial capital to secure promising GLP‑1 related programs. Viking’s drug candidate, VK2735—a dual GLP‑1/GIP receptor agonist—fits this profile precisely. Forthcoming Phase 3 VANQUISH trial Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
